Sustainability in the Biotechnologies and Pharmaceutical Sector: Progress on Targets, Gaps in Transparency and Implementation

EthiFinance analyses ESG ratings of 86 listed European companies

The sustainability of companies in the biotechnologies and pharmaceutical sector continues to improve. Nevertheless, there is a need for optimisation in key ESG areas: According to the analysis of 86 ESG ratings of European companies in the sector in 2024 (with reported data from 2023), more than two thirds (70 percent) scored between 31 and 70 points on a scale of 0 to 100.

In the three ESG pillars (‘Environment, Social, Governance’), companies perform best in the field of governance but achieve poor scores when it comes to social aspects.

Download the Press Release.